Kineta Chronic Pain, a subsidiary of Kineta, Inc., announced that it has entered into an exclusive option and license agreement with Genentech, a member of the Roche Group, to develop Kineta’s α9/α10 nicotinic acetylcholine receptor (nAChR) antagonists for the treatment of chronic pain.
The α9/α10 nAChR is a novel target for the treatment of chronic neuropathic pain. Preclinical data showed investigational compounds that specifically target the receptor reduced pain behaviors in animal models and demonstrated disease-modifying effects including reduced inflammation and nerve protection at the site of injury. This novel target is not believed to be expressed in the central nervous system and may lead to a safer therapy that is non-addictive and non-tolerizing.
Kineta, Inc. is an emerging biotechnology company that is focused on the translational development of first-in-class therapies from discovery to proof of concept. Kineta is developing a focused pipeline of novel drug candidates that address critical unmet patient needs in neuroscience, immuno-oncology, rare diseases and biodefense.